LLY Research Update — July 17, 2026
Updated Thesis
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatide leadership, manufacturing scale, payer infrastructure, brand, and a deep follow-on pipeline create meaningful competitive advantages, although product concentration and pricing pressure remain material. At $1,179.09, the shares trade at 41.73x trailing earnings, 34.32x EV/EBITDA, and 77.67x free cash flow, reflecting elevated expectations, but the valuation is classified as fair relative to its five-year history and the $1,552.32 fair-value estimate indicates 31.7% upside, supported by raised 2026 guidance, Foundayo adoption, and later-2026 retatrutide data.
The investment grade as of this refresh is A — high business quality. A-tier business, fair-tier valuation with 31.7% upside to $1,552.32 fair value and identifiable 2026 earnings and pipeline catalysts.
Grade Change
In this research cycle, the investment grade for Eli Lilly and Company moved from B to A. A-tier business, fair-tier valuation with 31.7% upside to $1,552.32 fair value and identifiable 2026 earnings and pipeline catalysts.
Key Metrics at a Glance
- Revenue growth: +55.5% year over year
- Net margin: 35.0%
- Fair value upside: +31.7% to our estimate of $1552
Current price: $1179.09
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Eli Lilly and Company remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full LLY research →](/stocks/LLY)